| |||||||||
Former Names B6.Cg-Tg(tTALap)5Uh/J (Changed: 15-DEC-04 ) Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse Generation N7 (11-DEC-05) Donating Investigator IMR Colony, The Jackson Laboratory Description
Hemizygous mice are viable and fertile. These transgenic mice carry the gene encoding the tetracycline-controlled transactivator protein (tTA) driven by the liver-enriched activator protein (PLAP, C/EBP, Cebpb) promoter, and express tTA, specifically, in liver. When these transgenic mice are mated to a strain carrying the luciferase gene coupled to a tetracycline-responsive promoter element (TRE; tetO), the luciferase reporter is expressed in a liver-specific fashion; treatment with doxycycline (dox) prevented transcription of the luciferase reporter in the liver. C57BL/6J-Tg(tTALap)5Uh mice may be mated to transgenic strains containing a gene of interest coupled to a TRE to study the effects of liver specific expression of the target gene in a dox-inducible fashion. Dox concentration may be administered in the animals' water supply. It should be noted that the chromosomal integration site of a TRE-couple transgene may affect the tissue-specific expression of the target gene, such that target gene expression is not limited to liver.
Strains carrying Tg(tTALap)5Bjd allele
006999 STOCK Dbttm1Geh Tg(tTALap)5Bjd Tg(tetO-DBT)A1Geh/J 003272 STOCK Tg(tTALap)5Bjd/J View Strains carrying Tg(tTALap)5Bjd (2 strains)
Strains carrying other alleles of tTA
007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003767 B6.Cg-Tg(Eno2tTA)5021Nes/J 003763 B6.Cg-Tg(Eno2tTA)5030Nes/J 005964 B6.Cg-Tg(GFAP-tTA)110Pop/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 003010 B6;CBA-Tg(Camk2a-tTA)1Mmay/J 008082 B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J 005625 FVB-Tg(Pcp2-tTA)3Horr/J 003170 FVB.Cg-Tg(Myh6-tTA)6Smbf/J 006209 FVB.Cg-Tg(Tal1-tTA)19Dgt/J 005942 FVB/N-Tg(Pf4-tTA/VP16)42Kra/J 004937 NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(tTALap)5Bjd Tg(tetO-DBT)A1Geh/J 003271 STOCK Tg(tTAhCMV)3Bjd/J 003275 STOCK Tg(tetL)1Bjd/J 003274 STOCK Tg(tetNZL)2Bjd/J View Strains carrying other alleles of tTA (18 strains)
Congenic Nomenclature
Tet Expression Systems
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Internal/Organ Research
Liver Defects
Research Tools
Tet Expression Systems (tTA/rtTA Expressing Strains)
| Allele Symbol | Tg(tTALap)5Bjd | ||
|---|---|---|---|
| Allele Name | transgene insertion 5, Hermann Bujard | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | LAP-tTA; Tg(tTALap)5Uh; | ||
| Mutation Made By | Hermann Bujard, Universität Heidelberg | ||
| Strain of Origin | NMRI | ||
| Site of Expression | Expresses tTA at high levels in the liver; see Stock No. 003563 | ||
| Expressed Gene | tTA, tetracycline-controlled transactivator, E. coli | ||
| The tetracycline-resistance gene (TetR), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). TetR was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). The tetracycline-inhibitable transcription factor is a component of a bigenic system that allows doxycycline (a tetracycline analog) regulatable expression of genes that are under the direction of the tetracycline responsive promoter (TetOp)promoter. | |||
| Promoter | Cebpb, CCAAT/enhancer binding protein (C/EBP), beta, rat | ||
| General Note | Transgenic mice on a C57BL/6J background are viable and fertile, and express tTA in the liver. | ||
| Molecular Note | This transgene contains the gene encoding the tetracycline regulated transactivator protein (tTA) driven by the rat Cebpb promoter (previously called liver-enriched activator protein). [MGI Ref ID J:93000] | ||
Genotyping Protocols
Tg(tTA), MCA, vers. 4
Tg(tTA), STD PCR, vers. 2
Tg(tTALap)5Bjd, SEP PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
Kistner A; Gossen M; Zimmermann F; Jerecic J; Ullmer C; Lubbert H; Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93(20):10933-8. [PubMed: 8855286] [MGI Ref ID J:93000]
Tg(tTALap)5Bjd relatedBeer S; Komatsubara K; Bellovin DI; Kurobe M; Sylvester K; Felsher DW. 2008. Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis. PLoS ONE 3(6):e2493. [PubMed: 18560566] [MGI Ref ID J:139884]
Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW. 2004. Developmental Context Determines Latency of MYC-Induced Tumorigenesis. PLoS Biol 2(11):E332. [PubMed: 15455033] [MGI Ref ID J:93372]
Carpenter B; Lin Y; Stoll S; Raffai RL; McCuskey R; Wang R. 2005. VEGF is crucial for the hepatic vascular development required for lipoprotein uptake. Development 132(14):3293-303. [PubMed: 15944181] [MGI Ref ID J:100427]
Hasan MT; Schonig K; Berger S; Graewe W; Bujard H. 2001. Long-term, noninvasive imaging of regulated gene expression in living mice. Genesis 29(3):116-22. [PubMed: 11252052] [MGI Ref ID J:127660]
Homanics GE; Skvorak K; Ferguson C; Watkins S; Paul HS. 2006. Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med Genet 7:33. [PubMed: 16579849] [MGI Ref ID J:119973]
Shachaf CM; Kopelman AM; Arvanitis C; Karlsson A; Beer S; Mandl S; Bachmann MH; Borowsky AD; Ruebner B; Cardiff RD; Yang Q; Bishop JM; Contag CH; Felsher DW. 2004. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431(7012):1112-7. [PubMed: 15475948] [MGI Ref ID J:93899]
Sun Y; Quinn B; Xu YH; Leonova T; Witte DP; Grabowski GA. 2006. Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model. J Lipid Res 47(10):2161-70. [PubMed: 16861620] [MGI Ref ID J:116525]
Tilli MT; Furth PA. 2003. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 5(4):202-5. [PubMed: 12817992] [MGI Ref ID J:84503]
Wang R; Ferrell LD; Faouzi S; Maher JJ; Bishop JM. 2001. Activation of the met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153(5):1023-34. [PubMed: 11381087] [MGI Ref ID J:69731]
Yang YA; Zhang GM; Feigenbaum L; Zhang YE. 2006. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9(6):445-57. [PubMed: 16766264] [MGI Ref ID J:110133]
Currently there no information available for this strain. This may be due to the supply level of this strain.
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.